Stock Financial Ratios, Dividends, Split History

CBIO / Catalyst Biosciences Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)138.57
Enterprise Value ($M)3.66
Book Value ($M)30.77
Book Value / Share2.59
Price / Book0.91
NCAV ($M)30.37
NCAV / Share2.55
Price / NCAV0.91
Share Statistics
Common Stock Shares Outstanding 6,081,230
Common Shares Outstanding 11,893,644
Preferred Stock Shares Outstanding 3,680
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.70
Return on Assets (ROA)-0.57
Return on Equity (ROE)-1.34
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio4.48
Income Statement (mra) ($M)
Revenue From Grants0.00
Sales Revenue Goods Net0.00
Contracts Revenue1,018,000.00
Collaboration Research And Development Revenue0.00
License And Services Revenue0.00
Operating Income-21.82
Net Income-21.56
Earnings Per Share Basic And Diluted-7.45
Earnings Per Share Diluted-7.45
Earnings Per Share Basic-7.45
Cash Flow Statement (mra) ($M)
Cash From Operations-19.94
Cash from Investing-11.25
Cash from Financing-19.94
Identifiers and Descriptors
Central Index Key (CIK)1124105
Related CUSIPS
14888D958 14888D909 14888D959 14888D208

Split History

Stock splits are used by Catalyst Biosciences Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

2018-07-20 seekingalpha
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement. (82-0)

Major Biopharma Catalysts on July’s FDA Calendar

2018-07-07 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside. (78-8)

Implied Volatility Surging for Catalyst Biosciences (CBIO) Stock Options

2018-06-19 zacks
Investors in Catalyst Biosciences, Inc. (CBIO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $25.00 Put had some of the highest implied volatility of all equity options today. (12-1)

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high. (474-6)

Small Caps Charge, Augurs Well For The Stock Market

2018-05-22 seekingalpha
Small cap stocks record fresh all-time highs leading the broader market indexes higher for the first time in a couple of years. (493-3)

CUSIP: 14888D109